NRG Therapeutics Ltd., backed by investors including Merck KGaA and Novartis, completed an oversubscribed £50 million (US$67 million) Series B financing. The company plans to progress its novel class of small-molecule mitochondrial permeability transition pore regulators into clinical testing for amyotrophic lateral sclerosis (ALS) and related neurodegenerative disorders. This substantial funding supports preclinical and clinical development, aiming to address unmet needs in ALS where mitochondrial dysfunction plays a central pathogenic role.